Beyond Full-Body MRI Scans: Other Cancer Screening Options
Huntsman Cancer Institute investigators explain who benefits from full-body MRIs, the risks involved with a screening, and how you can reduce your cancer risk.
Huntsman Cancer Institute investigators explain who benefits from full-body MRIs, the risks involved with a screening, and how you can reduce your cancer risk.
The T-cell engager CX-904 had a favorable safety profile when administered as monotherapy in patients with advanced or metastatic solid tumors.
The FDA has granted a breakthrough device designation to Teal Wand, an at-home screening test for cervical cancer.
The 17th Annual Hematologic Malignancies Demystified returns in 2025. Access our virtual CME conference and earn CME/CE credits with our renowned faculty. Led by conference…
Maurie Markman, MD, expands on the debate regarding the appropriate primary outcome end point for improved clinical benefit in a trial.
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
This Viewpoint discusses use of anti–PD-1 monotherapy as the primary treatment option for patients with treatment-naive metastatic melanoma staining positive for PD-L1 over dual checkpoint…
Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.
China’s NMPA has granted breakthrough therapy designation to IBI343 for use in select patients with claudin 18.2–positive gastric or GEJ adenocarcinoma.
Mohamad Mohty, MD, PhD, discusses unmet needs for patients with chronic or acute GVHD, for whom standard-of-care therapies often fall short.
In the first article of a 2-part series, Marc S. Hoffmann, MD, looks at the factors to take into consideration before initiating another line of…